Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
NVIDIA
NVDA
5
Broadcom
AVGO
US Stock MarketDetailed Quotes
BridgeBio Pharma (BBIO)
- 76.260
- -1.640-2.11%
Close Jan 15 15:59 ET
14.70BMarket Cap-18.11P/E (TTM)
77.850High74.300Low6.16MVolume75.010Open77.900Prev Close469.24MTurnover3.97%Turnover RatioLossP/E (Static)192.71MShares79.88052wk High-7.60P/B11.86BFloat Cap28.32552wk Low--Dividend TTM155.46MShs Float79.880Historical High--Div Yield TTM4.56%Range %4.980Historical Low76.116Avg Price1Lot Size
BridgeBio Pharma (BBIO) Key Financial Indicators
BBIO Earnings per Share (EPS)
According to the latest financial report of BridgeBio Pharma, the latest earnings per share (TTM) for the company is -0.95. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
BBIO Free Cash Flow (FCF)
Interested in knowing about BridgeBio Pharma's free cash flow? The latest report shows it as -112.44M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
BBIO Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of BridgeBio Pharma shows that the company's current ratio is 3.88, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
BBIO Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of BridgeBio Pharma, the quick ratio is 3.52, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
BBIO Return on Equity (ROE)
Want to learn more about the financial health of BridgeBio Pharma? The latest ROE figure is -108.26%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
BBIO Return on Assets (ROA)
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of BridgeBio Pharma, the total asset return on investment (ROA) is -17.58%.
Currency: USD
Quarterly
Loading...
BBIO Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check BridgeBio Pharma's latest financial report to see how their gross margin is doing - currently at 94.56%.
Currency: USD
Quarterly
Loading...
BBIO Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of BridgeBio Pharma, the net profit margin is -153.22%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Market Insights
Nancy Pelosi Portfolio Nancy Pelosi Portfolio
Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns. Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns.
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
The Fed Delivers Third Consecutive Rate Cut as Expected! How to Position for Year-End U.S. Equity Ma
On December 19, the Bank of Japan raised interest rates by 25 basis points as expected, in line with market forecasts. On the evening of Dec
今日熱門
Dec 11, 2025 03:27
December FOMC Interest Rate Meeting
牛牛課堂
Dec 19, 2025 12:28
[Opportunity Express] MRVL Continues to Bet on Optical Interconnects: Is Now a Good Time to Enter the Market?